MDxHealth (MDXH) EBT Margin (2022 - 2026)

MDxHealth (MDXH) posted EBT Margin of 32.38% for Q1 2026, up 8.89% sequentially from 35.54% in Q4 2025, and up 497.0% YoY from 5.42% in Q1 2025.

MDxHealth (MDXH) EBT Margin (2022 - 2026) Analysis & Trends

MDxHealth has reported EBT Margin for 5 years, with the latest figure at 32.38% in Q1 2026.

Quarterly EBT Margin rose 497.0% year-over-year to 32.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.81% (up 1666.0% YoY) and the FY2025 annual result came in at 32.79%, up 906.0% from the prior year.
EBT Margin rose to 32.38% in Q1 2026 per MDXH's latest filing, from 35.54% in the prior quarter.
Over five years, EBT Margin peaked at 0.16% in Q2 2025 and troughed at 122.21% in Q3 2022.
A 5-year average of 51.61% and a median of 46.55% in 2024 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2025: EBT Margin soared 7030 bps in 2023, then slumped 808 bps in 2025.
Over 5 years, EBT Margin stood at 95.49% in 2022, then soared by 42 bps to 55.26% in 2023, then surged by 50 bps to 27.46% in 2024, then fell by 29 bps to 35.54% in 2025, then gained by 9 bps to 32.38% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 32.38%, 35.54%, and 31.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn	16.04%
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn	17.21%
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn	34.29%
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn	22.23%
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn	6.89%
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn	-12.17%
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn	22.43%
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn	28.17%
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn	13.54%
10	MDxHealth	21.81 Mn	-21.34 Mn	16.61 Mn	-32.38%

Download Data